Neuroprotective therapies to be developed by Magnolia Neurosciences

Written by Sharon Salt, Editor

Accelerator Life Science Partners (Accelerator; NY, USA), a leading life science investment and management firm, has announced that is has launched Magnolia Neurosciences Corporation (NY, USA), which is a company developing a new class of neuroprotective medicines. The company was launched by Accelerator earlier this year and was co-funded by world-class researchers at the University of Texas MD Anderson Cancer Center (TX, USA). Magnolia Neurosciences will further develop discoveries made by scientists at MD Anderson and the Neurodegeneration Consortium. With a comprehensive approach to improving patient care, scientists from MD Anderson and the Neurodegeneration Consortium are focused on developing life-saving...

To view this content, please register now for access

It's completely free